Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05859490 · ClinicalTrials.gov registry record · Phase 1
Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination
A Phase 1 study of Immunization; Infection and Yellow Fever, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT05859490: Recruiting Phase 1 study of Immunization; Infection and Yellow Fever, sponsored by Oregon Health and Science University.
NCT05859490 is a Phase 1 study of Immunization; Infection and Yellow Fever that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 35 participants, below the 270-participant average among 4 other Immunization; Infection trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05859490, a Phase 1 study of Immunization; Infection and Yellow Fever, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to assess the immune response to the yellow fever vaccine 17D in adults with prior 17D vaccination. The main questions this study aims to answer are: * how does prior vaccination affect antibody responses to re-vaccination? * how does prior vaccination affect the immune cell response to re-vaccination? Participants will: * have been previously vaccinated with 17D. * be re-vaccinated with 17D. * provide medical and travel histories. * provide a blood sample prior to vaccination * provide a blood sample approximately every other day for 14 days after vaccination. * provide a blood sample approximately 28 days after vaccination. * complete a daily diary of symptoms following vaccination for 14 days. * report any additional symptoms after 14 days.
Primary Outcome
four-fold rise in neutralization antibody titer before and after vaccinatioin
Conditions Studied
Interventions
- BIOLOGICAL 17D
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
What NCT05859490 shows while recruiting
NCT05859490 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 270-participant average among 4 other Immunization; Infection trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Immunization; Infection appearing as the primary indexed condition, and to 1 intervention - of which 17D is the first listed.
NCT05859490 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT05859490 about?
NCT05859490 is a clinical study titled "Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination". The goal of this clinical trial is to assess the immune response to the yellow fever vaccine 17D in adults with prior 17D vaccination. The main questions this study aims to answer are: * how does prior vaccination affect antibody responses to re-vaccination? * how does prior vaccination affect the ...
What is the current status of trial NCT05859490?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2023-08-01. Estimated completion is 2025-12-31.
What conditions does trial NCT05859490 study?
This clinical trial studies the following conditions: Immunization; Infection, Yellow Fever.
What interventions are being tested in trial NCT05859490?
The interventions under investigation include: 17D (BIOLOGICAL).
Who is sponsoring clinical trial NCT05859490?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05859490 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immunization; Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI